newsfilter
← Latest News
PR Newswire·

Seelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004

SLS-004 Utilizes CRISPR-dCas9 to Target the SNCA Gene Responsible for the Expression of Alpha-Synuclein NEW YORK, Aug. 24, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the develop